Feasibility Trial of a Culturally Tailored Resilience Intervention for Underserved Breast Cancer Survivors (BRIGHT)
BRIGHT (Breast Cancer Resilience Intervention for Growth, Hope and Thriving): Co-Designing and Feasibility Testing a Culturally Tailored Resilience Intervention for Underserved Breast Cancer Survivors in Ireland
The goal of this feasibility trial is to find out whether a culturally tailored resilience intervention, called BRIGHT, can be delivered and tested with breast cancer survivors from underserved communities in Ireland. These include women from minority ethnic groups (including Travellers), migrant women, women living in rural areas and women experiencing socioeconomic disadvantage.
The main questions it aims to answer are:
- Can enough women be recruited and kept in the study?
- Do women attend the sessions and find the intervention acceptable?
- Can facilitators deliver the intervention as planned? Researchers will compare the BRIGHT resilience intervention with usual survivorship care plus a resource booklet. The results will show whether a larger, definitive trial is possible and will give early signals of benefit for psychological distress, fear of cancer recurrence, resilience, quality of life and unmet supportive care needs.
Participants will:
- Be randomly assigned to the BRIGHT resilience intervention or to usual care plus the BRIGHT Survivorship Resource Booklet
- In the BRIGHT group, attend 8 weekly 90-minute facilitated group sessions, in the community or online
- Complete questionnaires at the start, after 8 weeks and 3 months after the programme ends
- Be invited to take part in an interview about their experience (some participants only) Women in the usual care group will be offered the BRIGHT programme after their final follow-up.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Background: Women from underserved communities in Ireland often experience higher psychological distress, fear of cancer recurrence, unmet supportive care needs and barriers to survivorship services. Few psychosocial survivorship interventions have been designed or culturally adapted for these groups.
Intervention development: The BRIGHT resilience intervention is being developed in earlier stages of Project BRIGHT, a 42-month mixed methods study submitted for funding to Breast Cancer Now. These stages include a national survey of breast cancer survivors, interviews with women from underserved communities and a structured co-design process with survivors, clinicians, researchers and community stakeholders. Cultural adaptation is guided by Resnicow's Cultural Adaptation Framework and documented using FRAME.
Intervention: An 8-week hybrid programme of weekly 90-minute facilitated group sessions, delivered face to face in the community and through secure online sessions, with a participant workbook. Planned modules, subject to the co-design findings, are psychoeducation; emotional adjustment; managing fear of recurrence; culturally responsive coping and resilience; self-advocacy; healthcare navigation; peer support; and signposting to community resources. Materials will be translated into 2 to 3 priority languages.
Design: A two-arm parallel feasibility randomised controlled trial with 80 participants, individually randomised 1:1. A computer-generated, concealed allocation sequence will be managed by an independent researcher not involved in recruitment or intervention delivery. The comparator is usual survivorship care plus the BRIGHT Survivorship Resource Booklet, with delayed access to the BRIGHT programme after the 3-month follow-up (waitlist crossover). Allowing for up to 25% attrition, at least 60 participants are expected to be evaluable at final follow-up.
Data collection: Questionnaires at baseline (T0), after the intervention (T1, Week 8) and 3 months after the intervention (T2).
Progression criteria: Progression to a definitive trial will be guided by pre-specified traffic light criteria: at least 80% retention, at least 75% session completion, at least 85% intervention fidelity and a recruitment rate of at least 4 participants per site per month.
Process evaluation: Guided by the MRC Process Evaluation Framework, semi-structured interviews with 15 to 20 participants and facilitators will explore acceptability, barriers and facilitators to implementation, mechanisms of impact, fidelity and context. Fidelity will be assessed using facilitator session checklists, attendance records and independent review of a sample of recorded sessions.
Analysis: Feasibility outcomes will be reported using descriptive statistics with 95% confidence intervals. Exploratory analyses of secondary outcomes will estimate effect sizes and variance to inform the sample size for a future definitive trial.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Karina Correa Valdez
- Número de teléfono: +353 0833887830
- Correo electrónico: karina.correavaldez@ucd.ie
Copia de seguridad de contactos de estudio
- Nombre: Sinem Uzar Ozcetin Associate Professor in Mental Health Nursing
- Correo electrónico: sinem.uzarozcetin@ucd.ie
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Women aged 18 years or older.
- Diagnosis of breast cancer stage 0 to III.
- Completed primary treatment (surgery, chemotherapy and/or radiotherapy)
- Belong to at least one underserved group: minority ethnic group (including Irish Travellers), migrant or refugee, living in a rural area, or experiencing socioeconomic disadvantage.
- Living in Ireland
- Able to give informed consent, with interpreter support if needed
- Able to attend group sessions face to face or online
Exclusion Criteria:
- Metastatic (stage IV) breast cancer
- Severe mental health or cognitive difficulties that would prevent taking part in group sessions.
- Currently taking part in another psychosocial intervention study
- Took part in the BRIGHT co-design panel or user testing
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: BRIGHT Resilience Intervention
Participants attend the 8-week culturally tailored BRIGHT resilience intervention: weekly 90-minute |
A culturally tailored, co-designed group resilience programme for breast cancer survivors from underserved communities. Eight weekly 90-minute facilitated sessions, delivered in a hybrid format (community face to face and secure online). Planned modules: psychoeducation; emotional adjustment; managing fear of recurrence; culturally responsive coping and resilience; self-advocacy; healthcare navigation; peer support; and signposting to community resources. Delivered by trained facilitators using a standardised manual. Materials available in English and 2 to 3 priority languages. |
|
Comparador activo: Enhanced Usual Care
Participants receive standard oncology survivorship care plus the BRIGHT Survivorship Resource Booklet. They are offered the BRIGHT resilience intervention after the 3-month follow-up (waitlist crossover). |
BRIGHT Survivorship Resource Booklet A printed resource booklet with survivorship information and signposting to support services, given alongside standard oncology survivorship care. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Recruitment Rate
Periodo de tiempo: From start to end of recruitment, up to 6 months
|
Number of participants randomised per site per month. Progression target: at least 4 participants per site per month. |
From start to end of recruitment, up to 6 months
|
|
Retention
Periodo de tiempo: 3 months after the end of the intervention
|
Percentage of randomised participants who complete the 3-month follow-up questionnaires. Progression target: at least 80%. |
3 months after the end of the intervention
|
|
Session Attendance
Periodo de tiempo: During the 8-week intervention
|
Percentage of the 8 intervention sessions attended by participants in the BRIGHT arm, from attendance records. Progression target: at least 75% session completion. |
During the 8-week intervention
|
|
Intervention Fidelity
Periodo de tiempo: During the 8-week intervention
|
Percentage of planned session components delivered as intended, assessed using facilitator session checklists and independent review of a sample of recorded sessions. Progression target: at least 85%. |
During the 8-week intervention
|
|
Acceptability
Periodo de tiempo: Week 8 (end of the intervention)
|
Participant satisfaction with the intervention, measured using a questionnaire based on the Theoretical Framework of Acceptability, and explored in interviews with 15 to 20 participants and facilitators. |
Week 8 (end of the intervention)
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Depressive Symptoms
Periodo de tiempo: Baseline, Week 8 and 3 months after the end of the intervention
|
Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 to 27; higher scores mean more severe depressive symptoms. |
Baseline, Week 8 and 3 months after the end of the intervention
|
|
Anxiety Symptoms
Periodo de tiempo: Baseline, Week 8 and 3 months after the end of the intervention
|
Generalised Anxiety Disorder-7 (GAD-7). Scores range from 0 to 21; higher scores mean more severe anxiety. |
Baseline, Week 8 and 3 months after the end of the intervention
|
|
Fear of Cancer Recurrence
Periodo de tiempo: Baseline, Week 8 and 3 months after the end of the intervention
|
Fear of Cancer Recurrence Inventory, Short Form (FCRI-SF). Scores range from 0 to 36; higher scores mean greater fear of recurrence. |
Baseline, Week 8 and 3 months after the end of the intervention
|
|
Cancer-Specific Quality of Life
Periodo de tiempo: Baseline, Week 8 and 3 months after the end of the intervention
|
Functional Assessment of Cancer Therapy, Breast (FACT-B). Total scores range from 0 to 148; higher scores mean better quality of life. |
Baseline, Week 8 and 3 months after the end of the intervention
|
|
Psychological Resilience
Periodo de tiempo: Baseline, Week 8 and 3 months after the end of the intervention
|
Connor-Davidson Resilience Scale (CD-RISC). Higher scores mean greater resilience |
Baseline, Week 8 and 3 months after the end of the intervention
|
|
Unmet Supportive Care Needs
Periodo de tiempo: Baseline, Week 8 and 3 months after the end of the intervention
|
Supportive Care Needs Survey, Short Form (SCNS-SF34). Domain scores range from 0 to 100; higher scores mean greater unmet need. |
Baseline, Week 8 and 3 months after the end of the intervention
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- 2026.06EWPR1135
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
A decision on sharing anonymised individual participant data will be made before recruitment starts, in line with University College Dublin policy, funder requirements and GDPR.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .